Background Even though there are multiple options for the treatment of asthma, there still
exists a fair group of patients with difficult-to-control asthma. We describe for the first time the …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Background Omalizumab was introduced in Malta in 2011. To date, no local data have been
published. Objective To obtain baseline characteristics of our local cohort, determine …

Background Omalizumab is effective and safe in severe allergic asthma. Few data are
available about its impact on lung function and on asthma comorbidities, long-term follow-up …

Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …

Omalizumab is a humanized murine monoclonal antibody directed toward a portion of the
IgE indicated in Europe for the treatment of severe persistent allergic asthma, inadequately …

Background: Patients with severe persistent asthma who are inadequately controlled
despite treatment according to current asthma management guidelines have a significant …

Introduction Currently, omalizumab is indicated for the treatment of patients with severe
allergic uncontrolled asthma despite optimal therapy. Case presentation We studied a 52 …

BACKGROUND: A novel anti‐immunoglobulin E (anti‐IgE) therapy for asthma, omalizumab,
has been approved for use in Canada. OBJECTIVE: To review the basic and clinical data for …

Omalizumab, a monoclonal antibody that targets circulating IgE, is approved as add-on
therapy for adult and adolescent patients with severe allergic asthma in the EU and …